Novo Nordisk Falls 7% as Post-Wegovy Growth Plan Fails to Ease Competition Fears; Eli Lilly Slips, Viking Therapeutics Edges Higher
Novo Nordisk took the stage at its own capital markets day and said something that sent its stock…
Browsing Category